Hope springs for April inhibition

When news broke of Novartis’s $3.2bn acquisition of the kidney disease specialist Chinook Therapeutics yesterday, much of the focus fell on the latter’s lead project, atrasentan. But the deal was also likely driven by Chinook’s follow-on asset, the anti-April MAb zigakibart.